The MultiPlan Litigation: Why Every Provider Should Be Paying Attention

For years, many physicians, hospitals, ambulatory surgery centers, and specialty practices have shared a common frustration: out-of-network reimbursements that seemed increasingly disconnected from the actual cost of care. Now that frustration has evolved into one of the largest healthcare antitrust cases in the country.

MultiPlan—recently rebranded as Claritev—is at the center of a growing wave of litigation alleging that its reimbursement technology enabled major health insurers to systematically suppress out-of-network payments. While the company strongly denies wrongdoing, the legal challenges continue to expand, drawing participation from health systems, physician groups, state medical associations, attorneys general, and even the U.S. Department of Justice. For providers, the outcome could have far-reaching implications for reimbursement practices, payer negotiations, and the future use of pricing algorithms in healthcare.

What Is MultiPlan?

MultiPlan is a healthcare data analytics company that provides tools used by insurers to evaluate and reprice out-of-network claims. According to public court filings, insurers use MultiPlan’s technology and benchmarking tools to determine reimbursement recommendations for services delivered outside contracted provider networks. MultiPlan maintains that it does not set reimbursement rates and does not make final payment decisions; those decisions remain with the insurers themselves.

However, providers bringing lawsuits argue that the company’s technology became the foundation for a coordinated system that consistently reduced out-of-network payments across multiple payers.

Why Are Providers Suing?

The core allegation is relatively straightforward. Plaintiffs claim that competing insurers relied on the same reimbursement platform, shared pricing information through that platform, and ultimately paid providers artificially reduced amounts for out-of-network services.

According to the lawsuits, the result was widespread underpayment affecting physician practices, hospitals, surgery centers, behavioral health providers, and numerous other healthcare organizations. Some complaints estimate the alleged reimbursement reductions reached tens of billions of dollars annually.

Defendants strongly dispute these allegations. Claritev has repeatedly stated that it merely provides analytical tools and recommendations, does not determine payment amounts, and complies with federal and state antitrust laws. The participating insurers have similarly denied wrongdoing.

The Case Has Survived a Major Legal Test

One reason providers should pay attention is that the litigation has already passed an important milestone.

In 2025, a federal judge overseeing the consolidated litigation in Illinois denied key motions to dismiss, allowing major antitrust claims to move forward. The court concluded that providers had plausibly alleged an anticompetitive scheme sufficient to proceed into further litigation and discovery.

This does not mean the plaintiffs will ultimately win. However, it does mean the allegations were considered substantial enough to warrant continued judicial review rather than being dismissed at an early stage. For healthcare organizations, that distinction matters. Many large healthcare lawsuits never advance beyond preliminary procedural challenges. This one did.

Why the Department of Justice Became Involved

The case gained additional attention when the U.S. Department of Justice filed a statement supporting providers’ legal position regarding antitrust principles. Federal officials argued that the use of a common pricing algorithm does not automatically shield companies from antitrust scrutiny. The DOJ specifically emphasized concerns about situations where competing organizations may rely on shared algorithmic systems in ways that reduce competition. This aspect of the litigation may ultimately prove even more significant than the reimbursement dispute itself.

Healthcare organizations increasingly rely on artificial intelligence, predictive analytics, benchmarking tools, and automated pricing systems. The MultiPlan litigation may help define how antitrust law applies to these technologies moving forward.

The Lawsuits Keep Expanding

What began as provider litigation has continued to grow. More than 100 provider lawsuits have been consolidated into multidistrict litigation in federal court. Physician organizations, medical societies, hospitals, and healthcare systems across the country have joined the effort. Recent participants include state medical associations in New York, Texas, Minnesota, and other states.

In June 2026, Arizona Attorney General Kris Mayes filed a separate lawsuit against MultiPlan and several major insurers, alleging a coordinated scheme that harmed providers and increased financial burdens for patients receiving out-of-network care.

Meanwhile, similar litigation involving reimbursement technology vendor Zelis is progressing in federal court, suggesting that scrutiny of algorithm-driven reimbursement practices may extend beyond a single company.

What This Means for Providers

Regardless of the eventual outcome, the litigation highlights several operational realities.

• First, out-of-network reimbursement methodologies are receiving unprecedented legal scrutiny.
• Second, providers are increasingly challenging reimbursement reductions rather than simply accepting them as unavoidable payer policies.
• Third, the healthcare industry is entering a period in which algorithmic decision-making itself may face greater regulatory and legal examination.

Many providers participating in industry discussions argue that reimbursement methodologies have become increasingly opaque over the past decade, making it difficult to understand how payment amounts are determined. While courts have not yet ruled on the merits of the allegations, the litigation has already intensified calls for greater transparency.

***

The MultiPlan litigation is still in its early stages relative to the complexity of the allegations involved. Discovery, expert testimony, and additional court proceedings could continue for years.
Yet the case is already influencing conversations about healthcare competition, reimbursement transparency, payer-provider relationships, and the role of algorithms in financial decision-making.
For providers, this is not merely another lawsuit involving insurers.

It may become a defining case that shapes how out-of-network reimbursement is calculated, challenged, and regulated for years to come.

Sources

1. Becker’s Payer Issues. “What to Know About MultiPlan’s Litigation Saga” (June 2026).
2. Reuters. “US Judge Rules Health Insurers, MultiPlan Must Face Price-Fixing Lawsuits” (June 2025).
3. Reuters. “US Justice Department Backs Medical Providers’ Lawsuit Over Data Analytics Software” (March 2025).
4. Arizona Attorney General. “Attorney General Mayes Sues MultiPlan and Major Health Insurers for Alleged Price-Fixing Conspiracy” (June 2026).
5. Minnesota Medical Association. “MMA Joins Suit Against MultiPlan and Leading Insurance Providers Over Healthcare Price-Fixing” (June 2026).
6. Medical Society of the State of New York. “MSSNY Joins Lawsuit Against MultiPlan and Leading Insurance Providers” (April 2026).
7. Texas Medical Association. “TMA Joins Lawsuit Against MultiPlan and Leading Insurance Providers Over Health Care Price Fixing” (April 2026).